X
|
STUDENT DIGITAL NEWSLETTER ALAGAPPA INSTITUTIONS |
|
Nicholas P. Chandler BDS, MSc., PhD, LDS RCS (Eng), FDS RCPS (Glas) FDS RCS (Edin), FFD RCSI
Although individuals with sacroiliac or spinal diarthrodial joint erosion or fusion are easily recognizable as having spondyloarthropathy blood pressure medication green pill generic lanoxin 0.25 mg with visa, such findings may be lacking in more than half of humans affected by this disease (Rothschild & Martin arteria tibialis posterior purchase 0.25 mg lanoxin overnight delivery, 1993) blood pressure yoga generic 0.25 mg lanoxin amex. Similar patterns have been found in the zoological record (Rothschild & Martin heart attack xoxo buy generic lanoxin 0.25mg line, 1993). Recognition of spondyloarthropathy in the absence of sacroiliac/spine involvement and distinguishing it from other erosive disorders, such as rheumatoid arthritis, is the challenge. Spondyloarthropathy is herein applied as a generic term inclusive of several disorders which typically, but not invariably, affect the axial joints (spine or sacroiliac joints). Documented skeletal features characteristic of spondyloarthropathy include marginal and subchondral localization of erosions, para-erosional new bone formation, preservation of residual paraerosional trabeculae, enthesial calcification, zygoapophyseal joint fusion and erosions, costovertebral fusion and erosions, syndesmophytes, sacroiliac erosions and fusion, erosion of anterior-superior and anterior-inferior vertebral margins, pauciarticular pattern, limited distribution (fewer joints than in rheumatoid arthritis, even in those with polyarticular disease) and presence of patterns (including arthritis mutilans, all joints on a single digit and distal interphalangeal joint predominant, Rothschild & Woods, 1991). Although identification of the particular variety of spondyloarthropathy is predicated on fulfillment of specific criteria, not all individuals can be categorized. Salmonella, Shigella, enteropathic Escherichia coli, Yersinia, Camplyobacter and Chlamydia and perhaps Mycoplasma have been implicated (Granfors et al. We excluded a species if fewer than 10 specimens had been examined, as this could result in poor estimates of prevalence. We transformed prevalence (a proportion) by taking the arcsin of the square root (Sokal & Rohlf, 1995). For some analyses, statistical assumptions were violated and could not be rectified through data transformation; we therefore also report nonparametric statistics (the Spearman rank order correlation coefficient). We acquired data on body mass for primates (Smith & Jungers, 1997) and carnivores (Gittleman, 1985), along with data on life-history traits involving longevity, interbirth interval and age at first reproduction for primates (Ross & Jones, 1999), and longevity and age at sexual maturity for carnivores (Gittleman, 1986, 1989). All of the carnivore data were updated and verified from recent publications (Kitchener, 1991; Creel & MacDonald, 1995; Nowell & Jackson, 1996; Mills & Hofer, 1998; Creel & Creel, 2002; Sunquist & Sunquist, 2002; Macdonald & Sillero-Zubiri, 2004). For primates, data on home range size, day range length, group size, population density and diet (percentage of leaves and dichotomous categorization of fruit vs. Diet for carnivores was examined using both the percentage of meat in the diet and with a dichotomous categorization of meat vs. Population size was quantified as population density multiplied by geographic range size (Nunn et al. As a measure of mating promiscuity in primates, we used relative testes mass because this variable correlates with sperm competition and thus female mating promiscuity (Harcourt et al. We also used data on discrete categories of the number of mating partners from previous comparative studies of primates (Nunn et al. Substrate use in primates was coded on a threepart ranked scale: primarily use of the trees (arboreal), mixture of trees and ground and primarily use of the ground (terrestrial, based on data on substrate and habitat in Nunn & van Schaik, 2001). For carnivores, we also included a fourth category for aquatic carnivores (Gittleman, 1986, 1989; Bininda-Emonds & Gittleman, 2000), predicting highest levels of disease risk in these species (Nunn et al. Data on population density and diet for carnivores came from Gittleman & Harvey (1982) and Wrangham et al. Comparative analyses and statistical tests We analysed the data using standard statistical tests that treated each species value as statistically independent (nonphylogenetic tests), and then repeated the analyses using independent contrasts (Felsenstein, 1985) based on phylogenetic relationships in primates (Purvis, 1995) and carnivores (Bininda-Emonds et al. For all continuous, nondisease traits, we used log-transformed data and branch lengths. For both the phylogenetic and nonphylogenetic tests, we used multiple regression to identify predictor variables that best account for variation in percentage of specimens that were afflicted with spondyloarthropathy. Second, we addressed the possibility that multiple host traits influence spondyloarthropathy by analysing the data with a stepwise multiple regression model that included the following traits: body mass, longevity, population density, group size (primates only), home range size, per cent leaves or meat, residual testes mass (primates) or mating system (carnivores), substrate use and population size (carnivores). We used a forward stepwise procedure with all variables initially removed, sequentially adding variables with significance levels of P < 0. To control for correlations between body mass and other host traits, body mass was forced into the multiple regression model at all steps. Substrate use was treated as a continuous variable in the stepwise model (three or four-categories, see above), with increasing use of the ground (or water) scored as a higher value in the classification. We repeated the stepwise procedure with all variables entered in the model to check whether similar results were obtained. Finally, we tested whether the prevalence of spondyloarthropathy correlated with host threat level. We repeated analyses that controlled for variables found to be significant in the analyses of host traits. In phylogenetic tests, we treated threat level as a continuous variable, with higher threat levels indicated by larger values. Because we formulated a priori directional predictions for the effects of host traits on the prevalence of spondyloarthropathy, we used directed tests (Rice & Gaines, 1994) for investigating predictions. Directed tests allocate a disproportionate probability under the null hypothesis to the tail of the distribution in the predicted direction (c), while retaining a smaller probability in the opposite tail to detect unexpected deviations opposite to predictions (d < c). For the effect of threat level, we had no a priori hypotheses and so used two-tailed tests. Results General patterns After removing species with samples of fewer than 10 individuals, the mean prevalence of spondyloarthropathy in the samples was 5. Among carnivores, highest prevalence was found among the bears, Ursus arctos, Ursus maritimus and Helarctos malayanus (26. Spondyloarthropathy in primates Focused tests using species values revealed that the majority of the primate traits were statistically significant (Table 1). Counter to predictions, population density was negatively associated with prevalence of spondyloarthropathy, with this result statistically significant in a Table 1 Results from primates. For mating partner number and substrate use in nonphylogenetic tests, table shows F-statistics. For these analyses, monogamous and arboreal species tended to have lower prevalence of spondyloarthropathy (significant only for substrate). See Table 2 for analyses that used the Brunch algorithm for phylogenetic analysis of discrete traits. Day range length, percentage of leaves in the diet and residual testes mass were not significant. Given that most of the variables are highly correlated with body mass, many of the significant results in Table 1 could reflect a confounding effect of body mass. The negative association obtained for population density is further consistent with this possibility, as density correlates negatively with mass in mammals (Damuth, 1981). Thus, inclusion of body mass as a covariate eliminated all of the significant results, with only body mass emerging as statistically significant (Table 1). Thus, results for substrate use in primates are inconsistent across analyses, when compared with a more consistent pattern found with body mass in all analyses. Spondyloarthropathy in carnivores In focused tests using carnivore species values, body mass again emerged as the most significant predictor of the prevalence of spondyloanthropathy (Fig. As with results obtained in primates, other variables were statistically significant when body mass was not included as a covariate, including life-history traits, home range size and day range length (Table 3). Spondyloarthropathy was negatively associated with population density and also overall population size, again reaching significance in a directed test.
Try to be confident about your child and what they can do blood pressure chart graph buy lanoxin 0.25 mg without prescription, and welcome questions about them from other parent carers arrhythmia specialist generic 0.25 mg lanoxin with amex. Include your child in all family events blood pressure instrument order lanoxin 0.25mg on line, cultural and community celebrations hypertension with cardiac involvement proven lanoxin 0.25mg, activities, holidays, days out, cinema trips, etc. Take a week or fortnight off appointments and just enjoy family time or being with friends. If your child tires easily from walking, take their walking aid, wheelchair or tricycle out with you. If your child cannot easily access certain activities, then think about how they might be involved. For example, a child in a power chair could not join in the Ladders Game at Brownies, or play Guli Danda with friends due to health and safety issues, but instead they could control the game using their communication aid. The resource Games all children can play gives some ideas on inclusive play for all. Try to encourage your child to join a local group, such as Beavers, Rainbows, Brownies or Cubs, or specific cultural support groups, such as Chinese/Greek/Italian/Irish/black cultural heritage groups, etc. Or if they love football, basketball or another sport/leisure interest, find out about a local team they can join. Your local Family Information Services will have details of local groups, both mainstream and special needs services. Some practical issues may need to be addressed before your child with cerebral palsy can attend certain groups. This will explain all the key needs of your child to practitioners who are new to them. Contact the charity Sibs or your local Family Information Service for details, at When that person has cerebral palsy, they are dependent on a network of support from family, teachers, specialist support workers and health practitioners. Ideally your child will accompany you on the visits and will be actively involved in making the decision, but you will need to consider what is best for your child. Some young people can become very anxious when faced with change, so you may want to wait until you are ready to offer a choice of two schools. They should be able to show you how they will listen and respond to the views of the young person, too. What is the equalities and rights-respecting approach and the ethos of the school? Most secondary schools have very good websites, which can be used to support any discussions with your child and to help prepare them for the change. Brochures and prospectuses are also useful visual aids to support your discussions. If you choose a school outside the catchment area you may need to work with the school to set up these visits and arrange suitable transport. Transition visits enable young people to see the layout of the buildings, meet the staff, ask questions and prepare for the change. It is important that information is shared between the primary and secondary schools; parent carers will need to give permission for this to happen. It is likely that the schools will want to share information about specialist educational plans, assessments, individual needs and barriers to learning. It is important that good communication channels are established early on so that concerns and issues can be dealt with before they escalate. Some schools have virtual learning websites with an area for parent carers to liaise with staff. Every school will have an equal opportunities policy, and all members of staff should adhere to the Equalities Act 2010 and other related legislation. Some staff will have more experience than others in overcoming barriers to learning and it is important that you work with the school staff to improve their knowledge and understanding. Here, two young people with cerebral palsy share their experiences on bullying: "I was bullied. It looks at personal experiences of cerebral palsy, describing some of the feelings and emotions towards aspects of everyday life. Each and every person with cerebral palsy is affected in a different way and it is impossible to predict what the future will hold for your child. Children with cerebral palsy are children first, with their own personalities, cultural identities and potential to achieve. As they grow and develop into young people and adults, the questions and issues you have will change according to the life stage they are at and their individual circumstances. Nothing is impossible if you really want to do it, it just may take a bit of thinking and a lot of flexibility. Learning about and planning for the future, adapting to life in new and different ways and overcoming barriers are challenges that we all face, regardless of having an additional need. All people should be enabled to lead a life that is meaningful within a community that acknowledges, values and supports their differences. The life stages and life changes are the same for someone with cerebral palsy as they are for everyone else. Every person has a right to equality in everyday life, should be treated with dignity and respect, and supported to realise their individual potential and fulfil their ambitions and aspirations. Here two young people with cerebral palsy talk about independence: "College has helped me. Whilst physical abilities do decline with age, this happens more slowly and to a lesser degree than most people think. The impression that older people experience severe physical decline stems partly from confusion between primary ageing (changes brought about by increasing age) and secondary ageing (changes caused by disease and disuse or abuse of our bodies). However, for those who have lived a lifetime with a physical impairment, the effects of ageing can become apparent earlier than expected. Cerebral palsy is an example of a developmental disorder in which physical functioning can deteriorate with ageing as a result of poor mechanical efficiency. Whilst there is not a wealth of published scientific evidence on the physical effects of ageing and cerebral palsy, surveys have highlighted some of the problems that people encounter. What is clear is that people with cerebral palsy age in the same way as people without cerebral palsy, but some people with cerebral palsy can also experience secondary ageing effects. I have many more aches and pains around my joints and back; my balance has become poorer. Do not be afraid of talking to parent carers about how cerebral palsy affects their child. Many parent carers welcome the chance to share their feelings and having someone who will listen can make a real difference. Make a list of questions to ask and store them on your phone or print them out (see the meeting tips in the Who can help section for further pointers). However, you may need help from a range of people who have knowledge and experience of cerebral palsy and available services. Voluntary organisations and other parent carers will be able to give you information and direct you to services that can help. Practitioners you will meet along the way You are likely to come into contact with a number of practitioners over the coming months and years. They will be important partners for you and help you to get the best support for your child. Initially you may feel overwhelmed by the number of practitioners you have to deal with, particularly in the early days when they are all getting to know your child.
Cheap lanoxin 0.25 mg with mastercard. Helvetic Nerds - Mistaken Identity (Original Mix)(with Ultra Nate - Free by Rooli) 06.2010.
Vital signs: central line-associated blood stream infections-United States blood pressure regular purchase 0.25 mg lanoxin free shipping, 2001 heart attack exo buy 0.25 mg lanoxin free shipping, 2008 heart attack single lanoxin 0.25mg without a prescription, and 2009 arrhythmia young adults order lanoxin 0.25 mg without a prescription. Central line-associated bloodstream infection: is the hospital epidemiology of methicillin-resistant Staphylococcus aureus relevant? Catheter-related bacteremia and outcome of attempted catheter salvage in patients undergoing hemodialysis. Relationship between clinical outcomes and vascular access type among hemodialysis patients with Staphylococcus aureus bacteremia. Dialysis catheter-related septicaemia-focus on Staphylococcus aureus septicaemia. Risk factors for hematogenous complications of intravascular catheterassociated Staphylococcus aureus bacteremia. Venous thrombosis in patients with short- and long-term central venous catheter-associated Staphylococcus aureus bacteremia. Clinical practice guidelines for the diagnosis and management of intravascular catheterrelated infection: 2009 update by the Infectious Diseases Society of America. Reduction in central line-associated bloodstream infections among patients in intensive care units-Pennsylvania, April 2001-March 2005. Impact of a prevention strategy targeted at vascularaccess care on incidence of infections acquired in intensive care. Prospective randomised trial of povidone-iodine, alcohol, and chlorhexidine for prevention of infection associated with central venous and arterial catheters. Outcome of Staphylococcus aureus bacteremia according to compliance with recommendations of infectious diseases specialists: experience with 244 patients. Treatment of catheterrelated bacteraemia with an antibiotic lock protocol: effect of bacterial pathogen. Epidemiological investigation of local complications after cosmetic breast implant surgery in Denmark. Analysis of local complications following explantation of silicone breast implants. Infections of cerebrospinal fluid shunts: epidemiology, clinical manifestations, and therapy. Inflatable penile implant infection: predisposing factors and treatment suggestions. Coated implants and "no touch" surgical technique decreases risk of infection in inflatable penile prosthesis implantation to 0. Report on a case of staphylococcal pneumonia with staphylococcal septicaemia: treated with penicillin. Guidelines for the management of adults with hospital-acquired, ventilatorassociated, and healthcare-associated pneumonia. The pathogenesis of ventilatorassociated pneumonia: its relevance to developing effective strategies for prevention. Nseir S, Di Pompeo C, Pronnier P, Beague S, Onimus T, Saulnier F, Grandbastien B, Mathieu D, Delvallez-Roussel M, Durocher A. Nosocomial tracheobronchitis in mechanically ventilated patients: incidence, aetiology and outcome. Incidence, etiology, and outcome of nosocomial pneumonia in mechanically ventilated patients. The epidemiology of ventilator-associated pneumonia in a network of community hospitals: a prospective multicenter study. Epidemiology, etiology, and diagnosis of hospitalacquired pneumonia and ventilator-associated pneumonia in Asian countries. Morbidity and cost burden of methicillin-resistant Staphylococcus aureus in early onset ventilator-associated pneumonia. Clinical trial design for mild-to-moderate community-acquired pneumonia-an industry perspective. Microbial etiologies of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia. Carratala J, Mykietiuk A, Fernandez-Sabe N, Suarez C, Dorca J, Verdaguer R, Manresa F, Gudiol F. Health care-associated pneumonia requiring hospital admission: epidemiology, antibiotic therapy, and clinical outcomes. Association between Staphylococcus aureus strains carrying gene for PantonValentine leukocidin and highly lethal necrotising pneumonia in young immunocompetent patients. Severe communityacquired pneumonia due to Staphylococcus aureus, 2003-04 influenza season. Severe methicillinresistant Staphylococcus aureus community-acquired pneumonia associated with influenza-Louisiana and Georgia, December 2006-January 2007. Pulmonary manifestations in children with invasive community-acquired Staphylococcus aureus infection. Fatal community-associated methicillin-resistant Staphylococcus aureus pneumonia after influenza. How important is methicillin-resistant Staphylococcus aureus as a cause of community-acquired pneumonia and what is best antimicrobial therapy? Prevalence of methicillin-resistant Staphylococcus aureus as an etiology of community-acquired pneumonia. Refractory methicillin-resistant Staphylococcus aureus empyema invasion from a cervical abscess: report of a case. Methicillin-resistant Staphylococcus aureus infection and hospitalization in high-risk patients in the year following detection. Risk of infection and death due to methicillinresistant Staphylococcus aureus in long-term carriers. Risk factors for methicillin-resistant Staphylococcus aureus in patients with community-onset and hospitalonset pneumonia. Shindo Y, Ito R, Kobayashi D, Ando M, Ichikawa M, Shiraki A, Goto Y, Fukui Y, Iwaki M, Okumura J, Yamaguchi I, Yagi T, Tanikawa Y, Sugino Y, Shindoh J, Ogasawara T, Nomura F, Saka H, Yamamoto M, Taniguchi H, Suzuki R, Saito H, Kawamura T, Hasegawa Y. Risk factors for drug-resistant pathogens in community-acquired and healthcare-associated pneumonia. Venditti M, Falcone M, Corrao S, Licata G, Serra P, Study Group of the Italian Society of Internal Medicine. Outcomes of patients hospitalized with community-acquired, health care-associated, and hospital-acquired pneumonia. Risk factors for drug-resistant bacterial pneumonia in older patients hospitalized with pneumonia in a Chinese population. High prevalence of multidrug-resistant nonfermenters in hospitalacquired pneumonia in Asia. Is the present definition of health care-associated pneumonia the best way to define risk of infection with antibiotic-resistant pathogens? Garcia-Vidal C, Viasus D, Roset A, Adamuz J, Verdaguer R, Dorca J, Gudiol F, Carratala J. Low incidence of multidrug-resistant organisms in patients with healthcare-associated pneumonia requiring hospitalization. Validation of a clinical score for assessing the risk of resistant pathogens in patients with pneumonia presenting to the emergency department. A risk score for identifying methicillin-resistant Staphylococcus aureus in patients presenting to the hospital with pneumonia. Stratifying risk factors for multidrug-resistant pathogens in hospitalized patients coming from the community with pneumonia. Multidrug-resistant pathogens in hospitalised patients coming from the community with pneumonia: a European perspective. Poor prediction of potentially drug-resistant pathogens using current criteria of health care-associated pneumonia. Staphylococcus aureus sepsis and the Waterhouse-Friderichsen syndrome in children. Polymorphonuclear leukocytes mediate Staphylococcus aureus Panton-Valentine leukocidin-induced lung inflammation and injury. Poring over pores: alpha-hemolysin and Panton-Valentine leukocidin in Staphylococcus aureus pneumonia. Staphylococcus aureus alpha-hemolysin promotes platelet-neutrophil aggregate formation.
Even though the lymphocutaneous lesions have a classic presentation in many cases hypertension united states cheap lanoxin 0.25mg line, other diseases heart attack 29 year old female buy lanoxin 0.25 mg cheap, including atypical mycobacterial infections blood pressure medication irbesartan cheap 0.25mg lanoxin free shipping, nocardiosis arrhythmia 2 lanoxin 0.25mg with mastercard, and leishmaniasis, can produce lesions similar to those seen with sporotrichosis [32]. Because of its rarity and the similarity of clinical manifestations with those of other fungi and mycobacteria, the diagnosis of visceral infection with S. Material from cutaneous lesions should be aspirated or scraped with a scalpel blade, or a biopsy should be performed. The material that is cultured is incubated at room temperature to allow growth of the mold phase of S. Evidence from 1 well-designed clinical trial, without randomization; from cohort or case-controlled analytic studies (preferably from 11 center); from multiple time-series; or from dramatic results from uncontrolled experiments. Evidence from opinions of respected authorities, based on clinical experience, descriptive studies, or reports of expert committees. Therapy with AmB should be continued until the patient shows objective evidence of improvement; treat for a total of at least 12 months; may require long-term suppression with Itr. Histopathologic review of tissue samples reveals a mixed granulomatous and pyogenic inflammatory process. Serological testing has not proved to be very useful for the diagnosis of sporotrichosis and is not readily available. For decades, it has been known that hyperthermia decreases the size of the lesions of cutaneous sporotrichosis. Azoles have become the preferred agents for treatment of several forms of sporotrichosis. Ketoconazole was the initial azole used for sporotrichosis; however, it was not very effective, was associated with many adverse effects, and should no longer be used [37, 38]. Itraconazole supplanted ketoconazole for the treatment of the endemic mycoses and has become the agent of choice for sporotrichosis. Fluconazole therapy was ineffective, with only 3 (23%) of 13 patients with osteoarticular infection responding [20]. A small number of patients with pulmonary and disseminated sporotrichosis have been treated with itraconazole therapy, with mixed results [18]. Itraconazole comes in 2 oral dosage forms: a 100-mg capsule and a solution of 100 mg per 10 mL. Therapy should be initiated with a loading dose of 200 mg 3 times daily for 3 days. The capsule formulation of itraconazole is best absorbed when taken with food, and agents that decrease stomach acidity should be avoided. In contrast, itraconazole solution is best absorbed when taken on an empty stomach. If the patient tolerates the oral solution, it is the preferred formulation because of its improved absorption characteristics. For patients with visceral involvement with sporotrichosis and for those who have lymphocutaneous disease but are experiencing failure of therapy, serum levels of itraconazole should be determined to be certain that the patient has adequate absorption of drug. Because the half-life of the drug is long, there is little variation over a 24-h period; blood samples can be obtained at any time point, and the level should be 1 mg/mL. There are no published data regarding the new azoles, voriconazole and posaconazole. Amphotericin B remains the treatment of choice for patients with serious or life-threatening sporotrichosis. The experience in the literature is almost entirely with amphotericin B deoxycholate, but many clinicians, including the panel members, now prefer to use lipid formulations of amphotericin B, because such formulations have fewer adverse effects. There is no firm basis for picking one lipid formulation over another for the treatment of sporotrichosis, with the possible exception that the liposomal formulation might be preferred for treating meningitis. There are animal data (but no human data) noting that higher concentrations are achieved in brain tissue with liposomal amphotericin B, compared with amphotericin B lipid complex and amphotericin B deoxycholate [45]. However, the relevance of this finding to the treatment of meningeal sporotrichosis is unknown. There is little clinical experience using terbinafine for the treatment of sporotrichosis. However, 1 of only 2 randomized, controlled treatment trials for sporotrichosis involved this agent. Clinical improvement is often manifested within 4 weeks after starting therapy, and only a small number of patients need higher dosages of itraconazole or therapy with other antifungals. Although some of these studies reported on the use of a 100-mg daily dose, the panel felt that the success rate was too low with this dosage, and 200 mg administered daily should be the minimum dosage used. Terbinafine, administered to 5 patients at a dosage of 500 mg orally daily, resulted in a 100% cure rate [47], but results from a randomized, blinded treatment trial found only a 52% cure rate and a 21% relapse rate at 6 months after treatment among 28 patients receiving this dosage [46]. The same study showed an 87% cure rate and no relapses among 35 patients who received 1000 mg daily. Although adverse events were frequent, the majority were mild or moderate in severity and required stopping the drug for only 2 of 35 patients, both of whom were treated with the higher dosage. Only 3 of 12 patients who were cured received 200 mg daily, and the other patients were given different initial dosages but finished the course of therapy at a dosage of 400 mg daily. Among 14 enrolled patients, 9 were definitely or probably cured (64%), and another patient improved [20]. There are no studies reported with use of the newer azoles, voriconazole and posaconazole. The bulk of data supports the use of itraconazole for the initial treatment of osteoarticular sporotrichosis [18, 42]. Among the 11 responders, 4 experienced relapse when no longer receiving therapy, but all 4 had received 6 months of therapy. Amphotericin B is indicated for treating patients with extensive involvement or disease unresponsive to itraconazole. Success with amphotericin B therapy is similar to that with itraconazole therapy, although the drug is less well tolerated [13]. There have been reports of using intra-articular amphotericin B injections, but this form of therapy is rarely indicated [51]. In 1 openlabel treatment trial, 13 patients were treated, of whom 3 had a favorable response and 10 had persistent or progressive disease [20]. Surgical debridement for osteoarticular sporotrichosis is not commonly needed, but there are patients for whom drainage of a septic joint or removal of a sequestrum will prove to be beneficial. Surgical debridement as sole therapy for osteoarticular sporotrichosis is not effective. Data on treatment of pulmonary sporotrichosis are derived from 1 retrospective review, an openlabel treatment trial, and case reports. Pluss and Opal [19] described 55 cases that were treated before azoles became available; in this review, antifungal therapy alone often resulted in treatment failure. The authors concluded that the combination of amphotericin B therapy and surgical resection of the involved lung offered the best hope for long-term cure. Although most reported experience is with amphotericin B deoxycholate [52], the Expert Panel preferred to use lipid formulations of amphotericin B to decrease toxicity. Currently, amphotericin B, no matter which formulation is used, is rarely given for the entire course of therapy, as previously recommended in the 2000 guidelines.
References